6488
A. Potter et al. / Bioorg. Med. Chem. Lett. 20 (2010) 6483–6488
References and notes
1. Lu, K. P.; Zhou, X. Z. Nat. Rev. Mol. Cell Biol. 2007, 8, 904.
2. Weiwad, M.; Kullertz, G.; Schutkowski, M.; Fischer, G. FEBS Lett. 2000, 478, 39.
3. Brown, N. R.; Noble, M. E.; Endicott, J. A.; Johnson, L. N. Nat. Cell Biol. 1999, 1,
438.
4. Zhou, X. Z.; Kops, O.; Werner, A.; Lu, P. J.; Shen, M.; Stoller, G.; Küllertz, G.;
Stark, M.; Fischer, G.; Lu, K. P. Mol. Cell. 2000, 6, 873.
5. Lu, K. P.; Finn, G.; Lee, T. H.; Nicholson, L. K. Nat. Chem. Biol. 2007, 3, 619.
6. Bao, L.; Kimzey, A.; Sauter, G.; Sowadski, J. M.; Lu, K. P.; Wang, D. G. Am. J.
Pathol. 2004, 164, 1727.
7. Ayala, G.; Wang, D.; Wulf, G.; Frolov, A.; Li, R.; Sowadski, J.; Wheeler, T. M.; Lu,
K. P.; Bao, L. Cancer Res. 2003, 63, 6244.
8. Liou, Y. C.; Ryo, A.; Huang, H. K.; Lu, P. J.; Bronson, R.; Fujimori, F.; Uchida, T.;
Hunter, T.; Lu, K. P. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 1335.
9. Ryo, A.; Liou, Y. C.; Wulf, G.; Nakamura, M.; Lee, S. W.; Lu, K. P. Mol. Cell. Biol.
2002, 22, 5281.
10. Hennig, L.; Christner, C.; Kipping, M.; Schelbert, B.; Rücknagel, K. P.; Grabley, S.;
Küllertz, G.; Fischer, G. Biochemistry 1998, 37, 5953.
11. Rippmann, J. F.; Hobbie, S.; Daiber, C.; Guilliard, B.; Bauer, M.; Birk, J.; Nar, H.;
Garin-Chesa, P.; Rettig, W. J.; Schnapp, A. Cell Growth Differ. 2000, 11, 409.
12. Fila, C.; Metz, C.; van der Sluijs, P. J. Biol. Chem. 2008, 283, 21714.
13. Esnault, S.; Braun, R. K.; Shen, Z. J.; Xiang, Z.; Heninger, E.; Love, R. B.; Sandor,
M.; Malter, J. S. PLoS One 2007, 21, e226.
Figure 5. Compound 20 modulates biomarkers dependent upon Pin1 function. (a)
Transfection of siRNA vs. Pin1 reduces expression of cyclin D1, but cyclin E1 levels
are unaffected. (b) 6 h exposure to 20 reduces cyclin D1 levels, but cyclin E levels
are unaffected. (c) 20 min stimulation with insulin increases phosphorylation of
p70S6 kinase on Thr389; this response is blocked by 60 min pre-treatment with 20.
All data shown is from cells cultured in serum-free conditions for at least 24 h
before cells were harvested.
14. Zhang, Y.; Füssel, S.; Reimer, U.; Schutkowski, M.; Fischer, G. Biochemistry 2002,
41, 11868.
15. Wildemann, D.; Erdmann, F.; Alvarez, B. H.; Stoller, G.; Zhou, X. Z.; Fanghänel,
J.; Schutkowski, M.; Lu, K. P.; Fischer, G. J. Med. Chem. 2006, 49, 2147.
16. Zhao, S.; Etzkorn, F. A. Bioorg. Med. Chem. Lett. 2007, 17, 6615.
17. Liu, T.; Liu, Y.; Kao, H.-Y.; Pei, D. J. Med. Chem. 2010, 53, 2494.
18. Bayer, E.; Thutewohl, M.; Christner, C.; Tradler, T.; Osterkamp, F.; Waldmann,
H.; Bayer, P. Chem. Commun. (Camb). 2005, 516.
19. Daum, S.; Erdmann, F.; Fischer, G.; Féaux de Lacroix, B.; Hessamian-Alinejad,
A.; Houben, S.; Frank, W.; Braun, M. Angew. Chem., Int. Ed. 2006, 45, 7454.
20. Guo, C.; Hou, X.; Dong, L.; Dagostino, E.; Greasley, S.; Ferre, R. A.; Marakovits, J.;
Johnson, M. C.; Matthews, D.; Mroczkowski, B.; Parge, H.; VanArsdale, T.;
Popoff, I.; Margosiak, S.; Thomson, J.; Los, G.; Murray, B. W. Bioorg. Med. Chem.
Lett. 2009, 19, 5613.
combinations of surfaces on Pin1, providing opportunities to
improve potency and/or the physiochemical properties of the
compounds so that they occupy drug-like chemical space.
Improvements in both regards will be necessary to identify Pin1
inhibitors suitable for use as drugs: both of our medicinal chemis-
try programs directed against Pin1 have failed to find compounds
21. Dong, L.; Marakovits, J.; Hou, X.; Guo, C.; Greasley, S.; Dagostino, E.; Ferre, R.-A.;
Johnson, C.; Kraynov, E.; Thomson, J.; Pathak, V.; Murray, B. W. Bioorg. Med.
Chem. Lett. 2010, 20, 2210.
capable of modulating Pin1 activity in cells in the sub-lM range.
The nature of the Pin1 active site makes it difficult to optimise hits
into drug-like molecules: one end is dominated by three positively
charged residues, the other end is a narrow yet shallow hydropho-
bic pocket. The ligands we have identified as Pin1 inhibitors all
contain a carboxylate groups and the most potent compounds have
very low permeability in Caco-2 assays.22,31 The only way we have
found to obtain activity in cells has been to add lipophilic groups,
which has compromised the drug-likeness of our compounds. De-
spite our experiences, fragment based approaches to hit identifica-
tion remain attractive route towards finding Pin1 inhibitors,
because a wide region of chemical space can be sampled with a rel-
atively small compound library. Success, however, is contingent on
having suitable initial hits in the library to be screened.
22. Potter, A. J.; Ray, S.; Gueritz, L.; Nunns, C. L.; Bryant, C. J.; Scrace, S. F.;
Matassova, N.; Baker, L.; Dokurno, P.; Robinson, D. A.; Surgenor, A. E.; Davis, B.;
Murray, J. B.; Richardson, C. M.; Moore, J. D. Bioorg. Med. Chem. Lett. 2010, 20,
586.
23. Do, Q.-Q. T.; Guo, C.; Humphries, P. S.; Marakovits, J. T.; Dong, L.; Hou, X.;
Johnson, M. C. PCT Int. Appl. WO2006040646, 2006.
24. Baurin, N.; Aboul-Ela, F.; Barril, X.; Davis, B.; Drysdale, M.; Dymock, B.; Finch,
H.; Fromont, C.; Richardson, C.; Simmonite, H.; Hubbard, R. E. J. Chem. Inf.
Comput. Sci. 2004, 44, 2157.
25. Fischer, G.; Bang, H.; Berger, E.; Schellenberger, A. Biochim. Biophys. Acta 1984,
791, 87.
26. See Supplementary data.
27. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. J. Med. Chem. 2003, 46,
4265.
28. Zhang, Y.; Daum, S.; Wildemann, D.; Zhou, X. Z.; Verdecia, M. A.; Bowman, M.
E.; Lücke, C.; Hunter, T.; Lu, K. P.; Fischer, G.; Noel, J. P. ACS Chem. Biol. 2007, 2,
320.
29. Brackeen, M. F.; Stafford, J. A.; Feldmana, P. L.; Karanewsky, D. S. Tetrahedron
Lett. 1993, 34, 7873.
Acknowledgements
30. Leeson, P. D.; Springthorpe, B. Nat. Rev. Drug Disc. 2007, 6, 881.
31. Data not shown.
32. Moriya, O.; Minamide, H.; Urata, Y. Synthesis (Stuttgart) 1984, 12, 1057.
33. Ryo, A.; Uemura, H.; Ishiguro, H.; Saitoh, T.; Yamaguchi, A.; Perrem, K.; Kubota,
Y.; Lu, K. P.; Aoki, I. Clin. Cancer Res. 2005, 11, 7523.
The authors thank Dr. Martin Drysdale for valuable discussions,
Heather Simmonite for expert assistance with compound structure
determination by NMR spectroscopy and Dr. Loic Le Strat for chro-
matographic support.
34. Wulf, G. M.; Ryo, A.; Wulf, G. G.; Lee, S. W.; Niu, T.; Petkova, V.; Lu, K. P. EMBO J.
2001, 20, 3459.
35. Lee, N. Y.; Choi, H. K.; Shim, J. H.; Kang, K. W.; Dong, Z.; Choi, H. S.
Carcinogenesis 2009, 30, 671.
Supplementary data
Supplementary data associated with this article can be found, in